Binding molecule could improve injected radiotherapy

Actinium-225 is highly promising for use in Targeted Alpha Therapy owing to its 10-day half-life, which is compatible with antibody-based targets, and its high-energy, short-distance alpha emissions that are extremely lethal to cancer cells while largely sparing surrounding cells.
Cornell Chronicle